Obicetrapib for use in treating of cardiovascular disease (CVD) in his hyporesponders

HK40112025BActive Publication Date: 2026-07-17NEWAMSTERDAM PHARMA BV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
HK · HK
Patent Type
Patents
Current Assignee / Owner
NEWAMSTERDAM PHARMA BV
Filing Date
2024-11-26
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

There is an unmet need for safe and efficacious pharmacological treatment modalities for subjects who are hypo-responsive to high intensity statin therapy, as they do not show sufficient response to LDL-C reduction, leading to increased risk of atherosclerotic cardiovascular disease (ASCVD).

Method used

Combining high intensity statin therapy with the CETP inhibitor obicetrapib results in significant improvements in LDL-C, ApoB, and non-HDL-C levels, providing a synergistic effect that enhances lipid profile management in hypo-responders.

Benefits of technology

Obicetrapib, when added to high intensity statin therapy, reduces LDL-C levels by up to -50.8% and improves ApoB and non-HDL-C levels, effectively mitigating hypo-responsiveness and reducing ASCVD risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000025_0000
    Figure 00000025_0000
  • Figure 00000026_0000
    Figure 00000026_0000
  • Figure 00000026_0001
    Figure 00000026_0001
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.